Spike N501Y mutant SARS-CoV-2(2019nCoV) Pseudotyped virus production and Pseudovirus Based Neutralization Assay
(T,Test, formalized in 96 well, one test per well)
|Price(In USD)||Qty (Quantity)||Sum(In USD)|
|For larger scale||Click for inquiry.||Click for inquiry.|
SARS-CoV-2 spike-N501Y mutation
The world is in midst of the COVID-19 pandemic caused by SARS-CoV-2 (2019nCoV) infection. The Spike protein (S-protein) of SARS-CoV-2 (2019nCoV) mediates receptor (ACE2) binding and cell entry and is the dominant target of the immune system. Most mutations and deletions of SARS-CoV-2 occur in the coronavirus spike protein. Spike position N501, one of the key contact residues in the receptor-binding domain (RBD), and experimental data suggest mutation N501Y can increase ACE2 receptor affinity (Starr et al. 2020). N501Y has also been associated with increased infectivity and virulence in a mouse model (Gu et al. 2020).
Recently a novel SARS-COV-2 (2019nCOV) lineage, the B.1.1.7 lineage, with serials of site mutation, shows stronger infection ability in the UK. In SARS-COV-2 B.1.1.7 lineage, most mutations and deletions occur in the coronavirus spike protein. These mutantions also include SARS-CoV-2 spike- mutation. N501Y mutation is also found in the South Africa 501Y.V2 lineage.
GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) Spike-N501Y mutation
GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) spike-N501Y mutation
- 6th Floor, Building No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Email: [email protected]